Tango Therapeutics, Inc.
A clinical-stage biotechnology company developing precision cancer medicines, Tango Therapeutics uses a CRISPR-based platform to find genetic "weak spots" in tumor cells and build drugs that attack them. Founded in 2017 in the Boston area, the company takes its name from "synthetic lethality," a biological tango where two gene flaws together kill a cell, while either alone does not. Its lead drug candidate, vopimetostat, is being tested against pancreatic cancer.
Granted 475.0K · Bought 1.49M · Sold 225.0K
Sold 4.59M
Granted 5.0K
Sold 5.98M
Sold 2.70M
Bought 182.0K
Bought 533.5K · Sold 5.0K
Granted 320.1K · Sold 58.4K
Sold 584.7K
Granted 367.5K
Granted 142.7K · Sold 22.3K
Granted 31.7K
Granted 359.8K · Sold 254.7K
Granted 74.1K · Sold 8.1K
Granted 21.5K · Bought 20.0K
Granted 40.0K
Granted 24.9K
Granted 22.9K
Granted 17.5K
Granted 21.5K · Sold 5.0K
Granted 5.7K
Granted 5.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Boxer Asset Management Inc. +4 co-filersSee remarks · 8 transactions | — | 30.06Mas of Oct 2023 | 475.0K | 1.49M | 225.0K |
| Davis Aaron I. +1 co-filerSee remarks · 4 transactions | — | 17.51Mas of Nov 2024 | — | — | 4.59M |
| Davis Aaron I.Director · 1 transaction | — | 14.39Mas of Jun 2023 | 5.0K | — | — |
| TRV GP IV, LLC +2 co-filers10% owner · 24 transactions | — | 13.39M | — | — | 5.98M |
| EcoR1 Capital, LLC10% owner · 3 transactions | — | 10.63Mas of Nov 2024 | — | — | 2.70M |
| Boxer Asset Management Inc. +2 co-filers10% owner · 4 transactions | — | 7.05Mas of Oct 2022 | — | 182.0K | — |
| BCTG Holdings, LLC10% owner · 3 transactions | — | 6.99Mas of Aug 2021 | — | 533.5K | 5.0K |
| Weber BarbaraDirector, Executive Chair, Director · 10 transactions | — | 1.63M | 320.1K | — | 58.4K |
| Davis Aaron I. +1 co-filerSee remarks · 8 transactions | — | 597.3Kas of Jul 2024 | — | — | 584.7K |
| Peters MaltePresident & CEO, Director · 4 transactions | — | 367.5K | 367.5K | — | — |
| Beckman DaniellaChief Financial Officer · 10 transactions | — | 184.3K | 142.7K | — | 22.3K |
| Huang AlanChief Scientific Officer · 1 transaction | — | 167.6Kas of Mar 2023 | 31.7K | — | — |
| Crystal AdamPresident, R&D · 25 transactions | — | 136.6K | 359.8K | — | 254.7K |
| Barry DouglasGeneral Counsel · 7 transactions | — | 66.0Kas of Feb 2025 | 74.1K | — | 8.1K |
| Rothenberg MaceDirector · 6 transactions | — | 41.5K | 21.5K | 20.0K | — |
| Gall MatthewChief Financial Officer · 1 transaction | — | 40.0K | 40.0K | — | — |
| Ketchum John BDirector · 4 transactions | — | 24.9K | 24.9K | — | — |
| Lee SungDirector · 3 transactions | — | 22.9K | 22.9K | — | — |
| Borisy AlexisDirector · 3 transactions | — | 17.5Kas of Jun 2025 | 17.5K | — | — |
| Calhoun Lesley AnnDirector · 5 transactions | — | 16.5K | 21.5K | — | 5.0K |
| Azelby RobertDirector · 1 transaction | — | 5.7K | 5.7K | — | — |
| Huber Reid MDirector · 1 transaction | — | 5.0Kas of Jun 2023 | 5.0K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -12.21M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.